BMRN Financial Facts
Research and development: 160.83MTotal operating expenses: 339.98M
See Full Income Statement
Accumulated other comprehensive income (loss): 2.16M
Intangible assets, net: 561.39M
See Full Balance Sheet
BioMarin Pharmaceutical Inc. (BMRN) Earnings
|
Expand Research on BMRN
| Next EPS Date | 7/29/24 *Est. | EPS Growth Rate | +18.3% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +125.4% | Revenue Growth Rate | +8.8% *Last Qtr. |
| Average % Move 1-Wk after EPS | -3.0% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
4/28/16  |
 |
Q116 | -$0.53 | -$0.85 | +$0.32 | $236.7M | $240.21M |  |
 | | Details |
| 10/29/15 |
|
Q315 | -$0.60 | -$0.65 | +$0.05 | $208.9M | $216.61M | |
| | Details |
| 2/25/15 |
|
Q414 | -$0.47 | -$0.59 | +$0.12 | $230.9M | $189.01M | |
| | Details |
| 8/3/15 |
|
Q215 | -$0.51 | -$0.53 | +$0.02 | $250M | $218.16M | |
| | Details |
| 8/4/16 |
|
Q216 | -$2.61 | -$0.52 | -$2.09 | $300.1M | $278.16M | |
| | Details |
| 4/16/14 |
|
Q114 | N/A | -$0.46 | N/A | N/A | $145.5M | N/A | N/A | N/A | |
| 7/30/14 |
|
Q214 | -$0.23 | -$0.41 | +$0.18 | $191.8M | $159.7M | N/A | | | Details |
| 10/27/16 |
|
Q316 | -$0.26 | -$0.39 | +$0.13 | $279.9M | $289.44M | |
| | Details |
